Compare OFIX & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OFIX | ENTA |
|---|---|---|
| Founded | 1987 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 473.3M | 382.7M |
| IPO Year | 1998 | 2012 |
| Metric | OFIX | ENTA |
|---|---|---|
| Price | $11.32 | $12.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $17.25 | ★ $20.40 |
| AVG Volume (30 Days) | ★ 383.7K | 207.6K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.39 | ★ 29.93 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $822,312,000.00 | $102,814,000.00 |
| Revenue This Year | $6.13 | $7.76 |
| Revenue Next Year | $6.22 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 2.85 | ★ 16.48 |
| 52 Week Low | $8.85 | $6.45 |
| 52 Week High | $16.99 | $17.15 |
| Indicator | OFIX | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 53.87 | 42.37 |
| Support Level | $11.11 | $11.92 |
| Resistance Level | $12.40 | $13.97 |
| Average True Range (ATR) | 0.50 | 0.75 |
| MACD | -0.03 | -0.15 |
| Stochastic Oscillator | 34.88 | 14.52 |
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two reportable segments: Global Spine and Global Limb Reconstruction. The Global Spine segment offers bone growth therapies, spinal implants, biologics, and enabling technologies used in spinal procedures. The Global Limb Reconstruction segment provides products and solutions for limb deformity correction, limb lengthening, fracture management, and limb preservation, supported by digital technologies. It generates the majority of its revenue from the Global Spine segment.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.